ReviewHematology. American Society of Hematology. Education Program2021
Indications for transfusion in the management of sickle cell disease.
Review in Hematology. American Society of Hematology. Education Program, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 54 citations in OpenAlex.
- Role of Serum Ferritin in Predicting Outcomes of COVID-19 Infection Among Sickle Cell Disease Patients: A Systematic Review and Meta-Analysis.Frontiers in medicine · 2022Pooled it
- Transfusion strategies in thalassemia and sickle cell disease SITE-SIMTI-SIdEM Good Practice.Blood transfusion = Trasfusione del sangueGuideline
- Global Prevalence of Alloimmunization in Adults with Sickle Cell Disease Receiving Red Blood Cell Transfusions: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2026Review
- Effect of Red Blood Cell Transfusion on Inflammatory and Angiogenic Pathways in Patients With Sickle Cell Disease.American journal of hematology · 2026Article
- Article
- Transforming sickle cell haemotherapy in Africa: building safe, antigen-matched, available, and sustainable transfusion pathways.Frontiers in medicine · 2026Review
- Updated Review of Current Therapeutic Approaches for the Management of Sickle Cell Disease.Cardiovascular & hematological disorders drug targets · 2026Review
- Toxoplasma gondii seropositivity among patients with sickle cell disease: Prevalence and association with blood transfusion history.PloS one · 2026Article
- Optimizing the right time to start sickle cell therapies.Hematology. American Society of Hematology. Education Program · 2025Review
- Shoulder complications in sickle cell disease: Challenges, management strategies, and future directions.World journal of orthopedics · 2025Review
- Biosynthetic blood surrogates: Current status and future opportunities.Bioengineering & translational medicine · 2025Review
- Can health inequalities in sickle cell disease be addressed through novel therapies?HemaSphere · 2025Article
- Guidelines for the management of emergencies and critical illness in pediatric and adult patients with sickle cell disease.Annals of intensive care · 2025Review
- Position Paper on the Management of Sickle Cell Disease in Saudi Arabia: Understanding Disease Landscape, Identifying Challenges, and Exploring Opportunities in Transfusion Therapies.Journal of clinical medicine · 2025Review
- Challenges and opportunities for conceiving genetically diverse sickle cell mice.Trends in molecular medicine · 2025Review
- O blood usage trends in the pediatric population 2015-2019: A multi-institutional analysis.Transfusion · 2025Observational
- Beyond Childhood: Adult and Adolescent Sickle Cell Disease and Outcomes in Northern Ghana.EJHaem · 2025Article
- Clinical and Economic Burden of Managing Patients with Sickle Cell Disease Receiving Frequent Red Blood Cell Transfusions in the United States.ClinicoEconomics and outcomes research : CEOR · 2025Article
- Quality of Life and Out-of-Pocket Expenditures for Sickle Cell Disease Patients in Saudi Arabia: A Single-Center Study.Healthcare (Basel, Switzerland) · 2024Article
- First investigation of RH gene polymorphism in patients with sickle cell disease and associated blood donors in Cameroon, Central Africa.Blood transfusion = Trasfusione del sangue · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
The transfusion of red blood cells (RBCs) is a crucial treatment for sickle cell disease (SCD). While often beneficial, the frequent use of transfusions is associated with numerous complications. Transfusions should be offered with specific guidelines in mind. Here we present updates to the indications for transfusion of RBCs in SCD. We review recent publications and include expert perspectives from hematology and transfusion medicine. For some clinical indications, such as ischemic stroke, the role of transfusion has been well studied and can be applied almost universally. For many other clinical scenarios, the use of transfusion therapy has less conclusive data and therefore must be tailored to individual needs. We highlight the roles of RBC transfusions in preventing or mitigating neurological disease, in reducing perioperative complications, in managing acute chest syndrome, and in optimizing pregnancy outcomes in SCD. We further highlight various transfusion techniques and when each might be considered. Potential complications of transfusion are also briefly discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.